(1) Whether there is a shortage of vaccines as a result of manufacturing difficulties experienced by Onderstepoort Biological Products (OBP); if not, what is the position in this regard; if so, what (a) vaccines are in short supply and (b) are the further relevant details; (2) what measures have been put in place to ensure sustainable (a) manufacturing and (b) supply of vaccines?